FDA
approval
· 2022-05-04
FDA Approved: KISQALI FEMARA CO-PACK — Supplemental Application (Novartis Pharmaceuticals Corporation)
Summary
FDA approved a supplemental application to authorize Kisqali Femara Co-Pack, a co-packaged product combining ribociclib and letrozole for the treatment of breas…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for KISQALI FEMARA CO-PACK (LETROZOLE AND RIBOCICLIB)